An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
This treatment has been approved for sale to the public.
First Posted: August 1, 2002
Last Update Posted: January 7, 2014
Information provided by (Responsible Party):